Recent News

• 06.01.2026 - Cellectar Biosciences to Highlight Compelling New Efficacy Data from Phase 2b CLOVER WaM Study of Iopofosine I 131 in r/r Waldenström Macroglobulinemia at the American Society of Clinical Oncology Annual Meeting
• 05.14.2026 - Cellectar Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Updates
• 05.11.2026 - Cellectar Biosciences to Report First Quarter Financial Results and Host a Conference Call on Thursday, May 14, 2026
• 05.05.2026 - Cellectar Biosciences Reports Positive 12-Month Follow-Up Data from Phase 2b CLOVER WaM Study Demonstrating Durable Responses and Efficacy of Iopofosine I 131 in r/r Waldenström Macroglobulinemia
• 05.05.2026 - Cellectar Biosciences Announces Oversubscribed Financing Up to $140 Million

Recent Filings

• 05.29.2026 - S-1/A General form for registration of securities under the Securities Act of 1933
• 05.28.2026 - DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
• 05.28.2026 - DEF 14A Other definitive proxy statements
• 05.19.2026 - S-1 General form for registration of securities under the Securities Act of 1933
• 05.18.2026 - 8-K Current report
• 05.18.2026 - PRE 14A Other preliminary proxy statements
• 05.14.2026 - 8-K Current report
• 05.14.2026 - EX-99.1 EX-99.1
• 05.14.2026 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 05.11.2026 - 4 Statement of changes in beneficial ownership of securities